September 29, 2020

The Niche

Knoepfler lab stem cell blog

Matthew Porteus

2 min read

The exciting and sometimes downright crazy giant stem cell ecosystem of legit research and unproven stem cell clinics could use a dose of good news now and then. In today post, I highlight some upbeat news and some interesting recent pubs. Enjoy! From a team led by Hina Chaudhry, MD, Director of Cardiovascular Regenerative Medicine at the Icahn School of Medicine at Mt. Sinai, a new PNAS pub, “Multipotent fetal-derived Cdx2 cells from placenta regenerate the heart.” Congrats to first author Sangeetha Vadakke-MadathilThis is a …Read More

4 min read

Some in CRISPR-Cas9-land who are focused on potential future clinical applications are kind of rejoicing or at least sighing a breath of relief. This upbeat swing in the atmosphere (from investors especially) was sparked by retraction of that paper, the one initially reporting tons of supposed off-target CRISPR-Cas9 activity in mice, which turned out to be a “nothing burger” according to one investment site. Off-target activity definitely still needs to be on people’s radar screens, but it’s a problem that’s not nearly so widespread as that paper incorrectly …Read More

5 min read

The news that CRISPR-Cas9 gene editing in its current form may not work in a substantial fraction of people due to many of us having immunity to Cas9 came as a shock to many, but if you think about it, maybe it’s not so surprising. I don’t see it as the end of the world. A (preprint) from a group led by Matthew Porteus started this lively discussion a few days ago. The preprint is entitled, “Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans.” Some people are freaking …Read More

3 min read

By Heather Main I recently attended the UCSD Health CIRM Alpha Stem Cell Clinics Network Symposium at the Sanford Consortium, San Diego. There was of course some great academic research presented, including conflicting views on liver stem cell compartments from Roel Nusse and David Brenner, and advances in CRISPR technologies from Matthew Porteus. However, what struck me about this meeting was how well it presented patient need and churned emotions outside the normal excitement or skepticism of an academic/basic science conference. Shirley Johnson is …Read More